Zevra Therapeutics, Inc.
ZVRA
$12.23
-$0.45-3.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 58.26M | 124.22M | 83.23M | 35.33M | 2.64M |
| Total Depreciation and Amortization | 1.49M | 2.77M | 4.05M | 5.34M | 6.57M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.63M | -104.14M | -62.37M | -42.20M | -35.69M |
| Change in Net Operating Assets | -3.72M | -10.08M | -26.51M | -21.83M | -19.74M |
| Cash from Operations | 33.40M | 12.77M | -1.60M | -23.36M | -46.21M |
| Capital Expenditure | -775.00K | -771.00K | -835.00K | -866.00K | -312.00K |
| Sale of Property, Plant, and Equipment | 49.38M | 44.43M | 448.00K | 589.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 58.11M | 43.55M | 18.51M | 12.71M | -14.04M |
| Cash from Investing | 106.72M | 87.20M | 18.13M | 12.43M | -14.35M |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -60.09M | -60.09M | -372.00K | -372.00K | -372.00K |
| Issuance of Common Stock | 20.58M | 20.38M | 12.44M | 10.69M | 68.92M |
| Repurchase of Common Stock | -2.64M | -2.64M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | -42.14M | -42.35M | 12.06M | 10.31M | 68.55M |
| Foreign Exchange rate Adjustments | -367.00K | 633.00K | 28.00K | 1.02M | 466.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.61M | 58.26M | 28.62M | 400.00K | 8.45M |